Tag: Policy + Advocacy Updates

Colorado BioScience Association (CBSA) has released its 2024 CBSA Policy + Advocacy Report, which summarizes CBSA’s engagement during the Colorado legislative session, the regulatory processes to...

Colorado’s 2025 legislative session kicked off on Wednesday, January 8th, and will continue for 120 days until May 7th. Key issues that are top of mind for the Colorado life sciences ecosystem include...

As President-elect Donald Trump fills out his administration’s leadership ranks, the life sciences ecosystem is watching closely. Trump's nominees could significantly influence the landscape of health...

Last week, CBSA co-hosted an educational event for legislators and other stakeholders in partnership with PhRMA and Colorado Politics. The event featured a panel discussion that addressed the drivers...

After a long election season, the results are finally in (mostly). Overall, the theme of Colorado’s election results is “status quo.” At the State Capitol, Senate Democrats will continue to have a sim...

In October 2023, CBSA partnered with more than thirty leading organizations to launch the Partnership for the U.S. Life Science Ecosystem (PULSE), a coalition working to raise awareness of the fundame...

CBSA’s Policy + Advocacy team works year-round to represent Colorado’s life sciences ecosystem at the State Capitol. The bipartisan Colorado BioScience Political Action Committee (CBSA PAC) is a criti...

CBSA advocates for policies that sustain innovation and create high-wage, high value jobs in life sciences, including strong intellectual property (IP) protections, which are the foundation of technol...

Congress is grappling with a busy and complex agenda before adjourning on September 27 through the election. Congress is on track to meet its deadline of October 1 to pass a government funding measure...

The newly-announced “negotiated” prices for the first ten drugs subject to price controls under the Inflation Reduction Act (IRA) are set to go into effect for people with Medicare Part D prescription...